You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

The 2DR Era

Explore dolutegravir based, 2-drug regimens for your diverse patient needs.

Times are changing | 2DR Era

No one should take more medicines than they need

2DR: Meeting a clinical need

The HIV treatment landscape has changed dramatically over the past 30 years, with each decade serving as a foundation for the next to build upon. Today marks the beginning of the next era in HIV therapy...THE 2DR ERA.

Timeline of HIV Treatment
  • A 20-year-old starting a 3-drug regimen may be on therapy for nearly 6 DECADES, which translates to MORE THAN 60,000 DOSES of individual medications 6

See how a 2DR can benefit your patients

Juluca is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable ARV regimen for ≥6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI. 7

Dovato (Tivicay/Lamivudine) is indicated for the treatment of HIV-1 in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. 8

Learn More

DDIs=drug-drug interactions.

References:

  1. A timeline of HIV/AIDS. https://www.hiv.gov/sites/default/files/aidsgov-timeline.pdf. Accessed July 2019.
  2. Llibre JM, et al. J Antimicrob Chemother. 2016;71:856-861.
  3. Antiretroviral drugs used in the treatment of HIV infection. http://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm. Accessed July 2019.
  4. ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single pill for the treatment of HIV [news release]. London, UK: ViiV Healthcare group of companies; May 21, 2018. https://www.viivhealthcare.com/en-gb/media/press-releases/2018/may/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv/. Accessed July 2019.
  5. ViiV Healthcare. 2018 Press Release. ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine. Available at: https://www.viivhealthcare.com/media/press-releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-label-update-with-gemini-study-data-for-the-2-drug-regimen-of-tivicay-plus-lamivudine.aspx Accessed July 2019.
  6. The Antiretroviral Therapy Cohort Collaboration. Lancet HIV. 2017;4:e349-e356.
  7. JULUCA Summary of Product Characteristics.  Available from: https://www.medicines.ie/medicines/juluca-50-mg-25-mg-film-coated-tablets-34548/, last accessed July 2019.
  8. Dovato Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/dovato-50-mg-300-mg-film-coated-tablets-34871/smp last accessed January 2020

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.